CorMedix (CRMD) Expected to Announce Quarterly Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of $0.8160 per share and revenue of $127.0190 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.70). The company had revenue of $128.62 million for the quarter, compared to the consensus estimate of $127.02 million. CorMedix had a net margin of 52.31% and a return on equity of 52.30%. The company’s quarterly revenue was up 312.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.22 EPS. On average, analysts expect CorMedix to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

CorMedix Price Performance

Shares of CRMD stock opened at $6.71 on Friday. The company has a market capitalization of $530.43 million, a P/E ratio of 3.36 and a beta of 1.31. The company’s 50-day simple moving average is $7.09 and its two-hundred day simple moving average is $9.58. CorMedix has a one year low of $5.60 and a one year high of $17.43. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.11 and a quick ratio of 1.94.

CorMedix announced that its board has authorized a stock buyback plan on Monday, February 2nd that authorizes the company to buyback $75.00 million in shares. This buyback authorization authorizes the company to buy up to 12.3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Transactions at CorMedix

In related news, Director Alan W. Dunton sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total value of $260,000.00. Following the completion of the transaction, the director owned 40,250 shares of the company’s stock, valued at $523,250. The trade was a 33.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.10% of the stock is currently owned by insiders.

Institutional Trading of CorMedix

Several hedge funds and other institutional investors have recently bought and sold shares of CRMD. Comerica Bank increased its holdings in shares of CorMedix by 454.6% in the 3rd quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after acquiring an additional 2,205 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of CorMedix during the 2nd quarter worth $42,000. Kestra Advisory Services LLC purchased a new stake in shares of CorMedix during the 4th quarter worth $49,000. Caitong International Asset Management Co. Ltd boosted its position in CorMedix by 666.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock valued at $51,000 after purchasing an additional 3,813 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in CorMedix during the third quarter valued at about $55,000. Institutional investors own 34.18% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. HC Wainwright dropped their price objective on CorMedix from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Leerink Partners reaffirmed an “outperform” rating and set a $13.00 target price on shares of CorMedix in a research report on Friday, March 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a report on Wednesday, January 21st. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CorMedix in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada set a $13.00 price target on CorMedix and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CorMedix presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.